TTC39A: A Promising Drug Target and Biomarker for Ovarian Cancer

Target Name: TTC39A

NCBI ID: G22996

TTC39A

TTC39A: A Promising Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimated incidence of over 21,000 new cases and over 12,000 deaths in the United States alone in 2020. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer has remained relatively stagnant in recent years. Therefore, there is a growing interest in identifying new drug targets and biomarkers for the development of more effective and targeted therapies.

TTC39A: A Potential Drug Target and Biomarker

TTC39A is a shortened name for the protein TSP39, which is a key regulator of the T-cell receptor (TCR) signaling pathway. TSP39 is expressed in a variety of tissues and cells, including the intestine, skin, and tissues of the immune system. Recent studies have demonstrated that TSP39 plays a critical role in the regulation of immune responses and cancer growth.

In addition to its potential as a drug target, TSP39 has also been identified as a potential biomarker for ovarian cancer. Several studies have shown that higher levels of TSP39 are associated with poor prognosis in ovarian cancer patients. Furthermore, inhibition of TSP39 has been shown to enhance the effectiveness of chemotherapy in ovarian cancer.

The Potential Druggability of TTC39A

The drug targeting of TTC39A is based on its unique structure and its involvement in multiple cellular processes. TSP39 is a 21-kDa protein that consists of a N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-cell surface protein (TCP) domain. The TSP39 gene has been shown to encode a protein that is involved in the regulation of T-cell development, activation, and proliferation.

In addition to its involvement in T-cell biology, TSP39 has also been shown to play a critical role in the regulation of inflammation and cancer growth. Several studies have shown that TSP39 is involved in the regulation of inflammation-related signaling pathways, including the production of pro-inflammatory cytokines (2) and the regulation of immune cell function.

Furthermore, TSP39 has also been shown to be involved in the regulation of cell survival and metabolism. Several studies have shown that TSP39 is involved in the regulation of cell apoptosis (4) and in the regulation of cell metabolism.

The Potential Biomarker Properties of TTC39A

The potential biomarker properties of TTC39A make it an attractive target for drug development. As previously mentioned, TSP39 has been shown to be involved in the regulation of cancer growth and survival, which suggests that it may be a useful biomarker for ovarian cancer. In addition, TSP39 has been shown to be involved in the regulation of T-cell biology, which may make it a useful biomarker for the development of immunotherapy-based treatments.

The Druggability of TTC39A

The potential drugability of TTC39A is based on several factors. Firstly, TSP39 is a protein that is expressed in a variety of tissues and cells, which makes it an attractive target for drug development. Secondly, TSP39 has been shown to play a critical role in the regulation of multiple cellular processes, which suggests that it may have a wide range of potential functions as a drug target.

Thirdly, TSP39 has been shown to be involved in the regulation of cancer growth and survival, which makes it an attractive target for drugs that can inhibit its function. Lastly, TSP39 has

Protein Name: Tetratricopeptide Repeat Domain 39A

The "TTC39A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC39A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets